Loss of ARID1A sensitizes breast cancer cells to BET inhibition33, and most ARID1A mutated (ARID1AMUT) ovarian clear cell carcinomas showed relative sensitivity to BETi compared with ARID1A wild type (ARID1AWT) in vitro and inhibited tumor growth in vivo as monotherapy34. Here, ARID1A is linked to breast cancer.